Patients with relapsed or refractory diffuse large B-cell lymphoma have a poor prognosis. Glofitamab, a novel T-cell–engaging bispecific antibody, might improve outcomes in these patients. New research findings are summarized in a short video. https://nej.md/3UGxXF7 | The New England Journal of Medicine

Meet Lena, a survivor who faced stage 1 diffuse large B-cell lymphoma (DLBCL) head-on, and now, she shares her incredible journey from pre-diagnosis to life after cancer. It all began with what seemed like symptoms of a UTI—blood in her urine. Further investigations uncovered a bladder tumor. Unexpectedly, DLBCL was diagnosed post-surgery, despite the absence of typical signs. Lena candidly recounts the challenges of chemotherapy, from severe medication reactions to the emotional impact of hair